For many decades, cancer treatment has relied on surgery, chemotherapy, and radiation therapy. Over the past decade, immunotherapy, therapies that stimulate and strengthen the power of a patient's immune system to attack tumors, has rapidly become an important cog in the wheel of cancer treatment. One form of immunotherapy, called CAR T-cell therapy, has generated tremendous excitement among researchers and oncologists alike.
Chimeric antigen receptor (CAR)-T ceolls are genetically modified T cells that are collected from a patient's blood and modified in the lab to express a tumor antigen-specific cell- which has the specificity of antigen-binding domain from a B cell receptor making it specific for a type of the target cell, and it is fused to the intracellular domain of a CD3 T cell giving it the cytotoxic power to kill the specific cancer cell, hence the name Chimeric antigen receptor (CAR)-T cell.
EXPANDING THE REACH
Efforts are underway to address challenges related to manufacturing and scalability. Streamlining the production process and increasing the accessibility of CAR T-cell therapy could make it more readily available to patients around the world. India has a handful of companies which have either already received DCGI approval, or are in the process of receiving the same.
The Food and Drug Administration (FDA) has approved six CAR-T cell therapies for hematological cancers (blood cancers) since 2017. Kymriah (tisagenlecleucel) and Yescarta (axicabtagene ciloleucel) were the first two CAR-T products to receive approval. They are used for treating patients up to 25 years old with refractory or relapsed B-cell precursor acute lymphoblastic leukemia (ALL), and adults with refractory or relapsed diffuse large B-cell lymphoma (DLBCL) after two or more lines of systemic therapies.
This story is from the June 2024 edition of Healthcare Radius.
Start your 7-day Magzter GOLD free trial to access thousands of curated premium stories, and 9,000+ magazines and newspapers.
Already a subscriber ? Sign In
This story is from the June 2024 edition of Healthcare Radius.
Start your 7-day Magzter GOLD free trial to access thousands of curated premium stories, and 9,000+ magazines and newspapers.
Already a subscriber? Sign In
ADDRESSING INDIA'S RURAL CARE GAP
Lakhs of rural Indians lack access to healthcare services. Learn the ways India can improve healthcare accessibility in its rural areas.
iMeUsWe unveils at-home DNA testing services
iMeUsWe and MapMyGenome's at-home DNA testing to offer health and ancestry insights.
CAR T-CELL THERAPY: A PROMISING CANCER TREATMENT ADVANCEMENT
Employing genetically modified immune cells to attack tumors, CAR T-cell therapy offers new hope for cancer patients.
LEADING WITH INNOVATION
\"Every regional market presents a unique set of challenges and opportunities,\" said Ms Zahabiya Khorakiwala, Managing Director, Wockhardt Hospitals Group, during Healthcare Radius Leadership Vidcast.
OVERCOMING INDIA'S AMR CHALLENGE
India faces a growing threat of antimicrobial resistance (AMR). Experts warn of superbugs and ineffective treatments. Is there hope? Read on to find out.
SOCC launches online second opinion for pediatric care
SOCC’s online second opinion consultations for pediatric care aims to bridge the gap in pediatric healthcare services in India.
Clove Dental opens 12 clinics in a single day
Clove Dental marks its 13th anniversary with nationwide expansion. Get full details.
BM Birla Heart Hospital launches cardiac care program
BM Birla Heart Hospital partners with Dozee for Al-powered cardiac care program.
PD Hinduja Hospital goes digital for infection control
Ropes in Ibhar Technologies for infection control, patient safety, and auditing automation.
Maruti Suzuki marks one year of cardiac care in rural Gujarat
Maruti Suzuki celebrates one year of providing advanced cardiac care in rural Gujarat.